Aprea Therapeutics, Inc. (NASDAQ:APRE) Expected to Earn Q1 2024 Earnings of ($0.80) Per Share

Aprea Therapeutics, Inc. (NASDAQ:APRE) – Investment analysts at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for Aprea Therapeutics in a report released on Tuesday, March 26th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings per share of ($0.80) for the quarter. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Aprea Therapeutics’ current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for Aprea Therapeutics’ Q2 2024 earnings at ($0.80) EPS, Q3 2024 earnings at ($0.79) EPS, Q4 2024 earnings at ($0.14) EPS, FY2024 earnings at ($1.39) EPS, FY2025 earnings at ($0.58) EPS, FY2026 earnings at ($0.61) EPS, FY2027 earnings at ($0.68) EPS and FY2028 earnings at ($0.69) EPS.

Separately, Wedbush increased their price objective on Aprea Therapeutics from $9.00 to $11.00 and gave the stock an “outperform” rating in a research report on Wednesday.

Aprea Therapeutics Price Performance

Aprea Therapeutics stock opened at $6.69 on Friday. Aprea Therapeutics has a one year low of $2.78 and a one year high of $8.85. The firm has a market capitalization of $25.02 million, a P/E ratio of -1.68 and a beta of 1.05. The business has a fifty day moving average price of $6.39 and a 200-day moving average price of $5.01.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. BNP Paribas Arbitrage SNC bought a new position in shares of Aprea Therapeutics during the third quarter valued at about $40,000. Millennium Management LLC grew its stake in shares of Aprea Therapeutics by 35.7% during the fourth quarter. Millennium Management LLC now owns 164,626 shares of the company’s stock valued at $53,000 after buying an additional 43,293 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Aprea Therapeutics during the second quarter valued at about $54,000. Geode Capital Management LLC bought a new position in shares of Aprea Therapeutics during the second quarter valued at about $74,000. Finally, Vanguard Group Inc. grew its stake in shares of Aprea Therapeutics by 76.4% during the third quarter. Vanguard Group Inc. now owns 27,341 shares of the company’s stock valued at $114,000 after buying an additional 11,840 shares during the last quarter. 34.19% of the stock is owned by institutional investors.

Insider Buying and Selling at Aprea Therapeutics

In other news, Director Bernd R. Seizinger purchased 6,860 shares of the stock in a transaction on Wednesday, March 13th. The shares were acquired at an average price of $7.29 per share, for a total transaction of $50,009.40. Following the completion of the transaction, the director now directly owns 33,685 shares of the company’s stock, valued at approximately $245,563.65. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have bought 9,870 shares of company stock worth $71,952 over the last 90 days. Corporate insiders own 20.90% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers.